Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Bladder Cancer

Free Subscription 25.08.2025 1 ACS Biomater Sci Eng 1 ACS Sens 1 Ann Diagn Pathol 1 Ann Med 1 Ann Med Surg (Lond) 1 Ann Oncol 1 Ann Surg Oncol 1 ANZ J Surg 1 Biochim Biophys Acta Mol Basis Dis 1 BJGP Open 1 BJU Int 1 BMC Med Genomics 1 BMC Urol 1 BMJ 1 BMJ Open 1 Cancer Cell 1 Cancer Drug Resist 1 Cancer Gene Ther 1 Cancer Med 1 Cancer Radiother 1 Cancer Res Commun 1 Cell Death Dis 1 Clin Genitourin Cancer 1 Cureus 1 Curr Opin Urol 1 Cytotechnology 2 Diagn Pathol 3 Discov Oncol 1 Eur Radiol 2 Eur Urol Focus 1 Eur Urol Open Sci 1 Exp Cell Res 1 Expert Rev Anticancer Ther 1 Front Oncol 1 Genes Dis 1 Int J Surg 1 Int J Urol 1 Int Urol Nephrol 1 J Cell Mol Med 1 J Clin Invest 1 J Histotechnol 1 J Magn Reson Imaging 1 J Robot Surg 1 J Transl Med 1 Lancet Infect Dis 1 Mikrochim Acta 1 Mol Carcinog 1 Mol Med Rep 1 Nat Rev Urol 1 NPJ Precis Oncol 1 PLoS One 1 Proteomes 1 Radiat Oncol 3 Sci Rep 1 Toxicol Res (Camb) 7 Urol Oncol 1 Urol Pract

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

ACS Biomater Sci Eng

1. XU K, Gu D, Zhang Y, Su Q, et al
   Engineering Schottky Junction Nanocatalysts for Enhanced Charge Carrier Separation and Synergistic PDT/PTT/CDT in Bladder Cancer Therapy.
   ACS Biomater Sci Eng. 2025 Aug 24. doi: 10.1021/acsbiomaterials.5c00960.
   PubMed         Abstract available
   
   

   
   ACS Sens

2. MACHADO M, Yim W, Strano MS
   A Sensor Solution to the Femtomolar Problem in Bladder Cancer.
   ACS Sens. 2025 Aug 20. doi: 10.1021/acssensors.5c00670.
   PubMed         Abstract available
   
   

   
   Ann Diagn Pathol

3. GAO H, Ren D, Giannico GA, Akgul M, et al
   Do urinary bladder smooth muscle neoplasms show morphologic and immunophenotypic features of their uterine fumarate hydratase-deficient counterparts?
   Ann Diagn Pathol. 2025;79:152536.
   PubMed         Abstract available
   
   

   
   Ann Med

4. LUO W, Chen Y, Shen D, Zhang Y, et al
   Emotional stress: a prominent factor positively related to the onset and recurrence of bladder cancer as revealed by NHANES and a Chinese database.
   Ann Med. 2025;57:2549525.
   PubMed         Abstract available
   
   

   
   Ann Med Surg (Lond)

5. HASSAN IN, Ibrahim MNH, Abuassa N
   FDA approves durvalumab for muscle-invasive bladder cancer: a new standard in neoadjuvant and adjuvant therapy.
   Ann Med Surg (Lond). 2025;87:4011-4013.
   PubMed        
   
   

   
   Ann Oncol

6. HOFFMAN-CENSITS J, Tsiatas M, Chang PM, Kim M, et al
   Avelumab plus sacituzumab govitecan versus avelumab monotherapy as first-line maintenance treatment in patients with advanced urothelial carcinoma: JAVELIN Bladder Medley interim analysis.
   Ann Oncol. 2025;36:1088-1095.
   PubMed         Abstract available
   
   

   
   Ann Surg Oncol

7. LAI S, Wu P, Liu J, Song Y, et al
   Assessing the Influence of Bladder Cancer on Upper Tract Urothelial Carcinoma Prognoses Following Radical Nephroureterectomy: A Retrospective, Propensity Score-Based Multicenter Cohort Study.
   Ann Surg Oncol. 2025 Aug 25. doi: 10.1245/s10434-025-17808.
   PubMed         Abstract available
   
   

   
   ANZ J Surg

8. OH C, Bourlotos G, O'Callaghan M, Grundy L, et al
   BCG Intolerance in Nonmuscle Invasive Bladder Cancer-A Systematic Review.
   ANZ J Surg. 2025 Aug 20. doi: 10.1111/ans.70281.
   PubMed         Abstract available
   
   

   
   Biochim Biophys Acta Mol Basis Dis

9. MATSUDA E, Hasebe S, Matsuzaka T, Hayashi A, et al
   Inhibition of ELOVL6 activity impairs mitochondrial respiratory function and inhibits tumor progression in FGFR3-mutated bladder cancer cells.
   Biochim Biophys Acta Mol Basis Dis. 2025;1871:168023.
   PubMed         Abstract available
   
   

   
   BJGP Open

10. YAU STY, Leung EYM, Hung CT, Wong MC, et al
    Interaction patterns amongst risk factors for bladder cancer in adults with type 2 diabetes managed in primary care.
    BJGP Open. 2025 Aug 22:BJGPO.2025.0028. doi: 10.3399/BJGPO.2025.0028.
    PubMed         Abstract available
    
    

    
    BJU Int

11. ZAURITO P, Scilipoti P, Longoni M, Viti A, et al
    The value of maintenance therapy in intermediate-risk non-muscle-invasive bladder cancer.
    BJU Int. 2025 Aug 22. doi: 10.1111/bju.16905.
    PubMed         Abstract available
    
    

    
    BMC Med Genomics

12. LV Z, Zhao S, Wu H
    Correction: LIMA1 inhibits cisplatin resistance and malignant biological behavior of bladder cancer cells by suppressing the Wnt/beta-catenin pathway.
    BMC Med Genomics. 2025;18:130.
    PubMed        
    
    

    
    BMC Urol

13. KARLSSON L, Ek-Steinum A, Nyman V, Abuhasanein S, et al
    Patients' experiences of a standardized care pathway for suspected bladder cancer due to macroscopic hematuria.
    BMC Urol. 2025;25:216.
    PubMed         Abstract available
    
    

    
    BMJ

14. BOWIE K
    Bladder cancer: "Breakthrough" treatment that doubles survival rates is approved for NHS patients.
    BMJ. 2025;390:r1786.
    PubMed        
    
    

    
    BMJ Open

15. VAN KOEVERDEN SW, van Hoogstraten LM, de Rooij M, van der Leest M, et al
    Multiparametric MRI for local staging in patients with suspected muscle-invasive bladder cancer: study protocol for a multicentre, non-inferiority randomised controlled trial (the BladParadigm study).
    BMJ Open. 2025;15:e100002.
    PubMed         Abstract available
    
    

    
    Cancer Cell

16. DAMAN AW, Antonelli AC, Redelman-Sidi G, Paddock L, et al
    Microbial cancer immunotherapy reprograms hematopoiesis to enhance myeloid-driven anti-tumor immunity.
    Cancer Cell. 2025;43:1442-1459.
    PubMed         Abstract available
    
    

    
    Cancer Drug Resist

17. HU C, Wei S, Zhu W, Lv B, et al
    IRE1alpha modulates M1 oncolytic virus sensitivity via ER stress regulation in bladder cancer.
    Cancer Drug Resist. 2025;8:41.
    PubMed         Abstract available
    
    

    
    Cancer Gene Ther

18. LU Y, Ye F, Han X, Wang Z, et al
    Integrated spatial transcriptome and metabolism study reveals metabolic heterogeneity in human bladder cancer.
    Cancer Gene Ther. 2025 Aug 16. doi: 10.1038/s41417-025-00947.
    PubMed         Abstract available
    
    

    
    Cancer Med

19. 
    RETRACTION: Silencing Circular RNA VANGL1 Inhibits Progression of Bladder Cancer by Regulating miR-1184/IGFBP2 Axis.
    Cancer Med. 2025;14:e71178.
    PubMed         Abstract available
    
    

    
    Cancer Radiother

20. SARGOS P, Sauvage LM, Khalifa J, Riou O, et al
    Role of radiotherapy in the management of bladder cancer: Recommendations of the French Society for Radiation Oncology, 2025 update.
    Cancer Radiother. 2025;29.
    PubMed         Abstract available
    
    

    
    Cancer Res Commun

21. LEE HJ, Gulati R, Sayar E, Patel RA, et al
    Patterns of HER2 Expression in Metastatic Prostate and Urothelial Cancers: Implications for HER2-Targeted Therapies.
    Cancer Res Commun. 2025;5:1419-1428.
    PubMed         Abstract available
    
    

    
    Cell Death Dis

22. DAI M, Yuan X, Sun C, Han R, et al
    The ETS transcription factor GABPA inhibits bladder cancer aggressiveness by repressing extracellular matrix deposition and mechanotransduction signaling.
    Cell Death Dis. 2025;16:618.
    PubMed         Abstract available
    
    

    
    Clin Genitourin Cancer

23. JAIME-CASAS S, Zugman M, Barragan-Carrillo R, Ebrahimi H, et al
    Clinical and Pathological Predictors for Occult Lymph Node Involvement in Patients With Clinical Node-Negative Bladder Cancer Undergoing Radical Cystectomy.
    Clin Genitourin Cancer. 2025 Jul 23:102405. doi: 10.1016/j.clgc.2025.102405.
    PubMed         Abstract available
    
    

    
    Cureus

24. SZYMKIEWICZ S
    Suspected Urine-Induced Chemical Peritonitis Secondary to Invasive Bladder Cancer: A Case Report.
    Cureus. 2025;17:e90092.
    PubMed         Abstract available
    
    

    
    Curr Opin Urol

25. BRACCO FM, Wong CHM, Teoh JYC
    Antibody-drug conjugates for non-muscle invasive bladder cancer: current status and future development.
    Curr Opin Urol. 2025 Aug 25. doi: 10.1097/MOU.0000000000001330.
    PubMed         Abstract available
    
    

    
    Cytotechnology

26. WANG G, Han M, Chen F, Liu J, et al
    LINC00152 knockdown exerts repressive effects on epithelial-mesenchymal transition in bladder cancer.
    Cytotechnology. 2025;77:166.
    PubMed         Abstract available
    
    

    
    Diagn Pathol

27. HOOSHMAND F, Mokhtari M, Aminnia S, Dashtestani A, et al
    PD-1 and PD-L1 expression in molecular subtypes of muscle-invasive bladder cancer: immunohistochemical characterization and correlation with clinicopathological features.
    Diagn Pathol. 2025;20:97.
    PubMed         Abstract available
    
    
28. NEDJADI T, Ahmed ME, Ansari HR, Aouabdi S, et al
    The clinical value of the EpCAM biomarker and its association with immune cell infiltration in bladder cancer.
    Diagn Pathol. 2025;20:96.
    PubMed         Abstract available
    
    

    
    Discov Oncol

29. ALSOUFI F, Zetoune AB
    High mobility group A2 (HMGA2) protein tissue levels and its association with clinicopathological features in bladder cancer patients.
    Discov Oncol. 2025;16:1622.
    PubMed         Abstract available
    
    
30. ZHAO Y, Wu X, Zheng Y, Bai H, et al
    Prognostic value of LncRNA DLGAP1-AS2 in bladder cancer and its regulatory effect on tumor progression.
    Discov Oncol. 2025;16:1578.
    PubMed         Abstract available
    
    
31. WANG L, Chen P, Liu H, Qin J, et al
    A nomogram integrating mutation signatures and clinical features for prognostic stratification in bladder cancer.
    Discov Oncol. 2025;16:1562.
    PubMed         Abstract available
    
    

    
    Eur Radiol

32. ARITA Y, Edo H, Yoshida S
    Structured MRI assessment after neoadjuvant therapy for bladder cancer: the emerging roles of NacVI-RADS and multimodal AI.
    Eur Radiol. 2025 Aug 15. doi: 10.1007/s00330-025-11934.
    PubMed        
    
    

    
    Eur Urol Focus

33. HE W, Wang M, Zhang C, Zeng S, et al
    Re: Thomas Dreyer, Simone Brandt, Fabrin Knud, et al. Use of the Xpert Bladder Cancer Monitor for Guiding Cystoscopy in High-grade Non-muscle-invasive Bladder Cancer: Results from the Randomized Controlled DaBlaCa-15 Trial. Eur Urol 2025;88:23-30.
    Eur Urol Focus. 2025 Aug 20:S2405-4569(25)00250.
    PubMed        
    
    
34. SILVA-FERREIRA M, Lopes-Conceicao L, Monteiro-Reis S, Henrique R, et al
    Reply to Hao Wang and Li Yang's Letter to the Editor re: Mariana Silva-Ferreira, Joao A. Carvalho, Sofia Salta, et al. Diagnostic Test Accuracy of Urinary DNA Methylation-based Biomarkers for Bladder Cancer: Considerations for Further Research. Eur Ur
    Eur Urol Focus. 2025 Aug 23:S2405-4569(25)00246.
    PubMed        
    
    

    
    Eur Urol Open Sci

35. SUARTZ CV, de Lima RD, de Almeida LS, Liebl B, et al
    Neoadjuvant Immunotherapy in Bladder Cancer: Ushering in a New Era of Treatment-A Systematic Review of Current Evidence.
    Eur Urol Open Sci. 2025;79:45-59.
    PubMed         Abstract available
    
    

    
    Exp Cell Res

36. YANG D, Mao W, Jiang L, Liu B, et al
    CALD1-derived circ-0003746 targeting miR-526b promotes EMT-mediated bladder cancer progression.
    Exp Cell Res. 2025 Aug 14:114710. doi: 10.1016/j.yexcr.2025.114710.
    PubMed         Abstract available
    
    

    
    Expert Rev Anticancer Ther

37. EMTIAZI N, Zolfi E, Khaleghi Mehr F
    Genetic investigation in patients with histological variants of bladder cancer: clinical implications.
    Expert Rev Anticancer Ther. 2025 Aug 25:1-23. doi: 10.1080/14737140.2025.2548487
    PubMed         Abstract available
    
    

    
    Front Oncol

38. LI D, Xu JN, Chen HK, Ren Q, et al
    Comparative efficacy of holmium laser versus plasma techniques in the surgical management of non-muscle invasive bladder cancer: a meta-analysis.
    Front Oncol. 2025;15:1625901.
    PubMed         Abstract available
    
    

    
    Genes Dis

39. SHI Q, Pan X, Zhang S, Wu M, et al
    Menin facilitates the cell proliferation of bladder cancer via modulating the TFAP2C/beta-catenin axis.
    Genes Dis. 2025;12:101565.
    PubMed         Abstract available
    
    

    
    Int J Surg

40. LI H, Zeng S, Yang C, Yang Y, et al
    Global, regional, and national burden and trends of bladder cancer in individuals Aged 55 Years and older From 1990 to 2021: Findings from the Global Burden of Disease Study 2021.
    Int J Surg. 2025 Aug 21. doi: 10.1097/JS9.0000000000003254.
    PubMed         Abstract available
    
    

    
    Int J Urol

41. KAWAHARA T
    Re: Recent Advances and Future Directions in Bladder Preservation Therapy for Muscle-Invasive Bladder Cancer.
    Int J Urol. 2025 Aug 14. doi: 10.1111/iju.70199.
    PubMed        
    
    

    
    Int Urol Nephrol

42. LIU X, Wang Y, Wang Z, Shao B, et al
    Chemotherapy-enhanced endoscopic submucosal En Bloc dissection vs. conventional TURBT for NMIBC: a comparative study.
    Int Urol Nephrol. 2025;57:2755-2765.
    PubMed         Abstract available
    
    

    
    J Cell Mol Med

43. YE S, Liufu C, Yin C, Zhu T, et al
    MiR-20a-5p Inhibits Bladder Cancer Proliferation and Migration by Targeting KPNA2.
    J Cell Mol Med. 2025;29:e70785.
    PubMed         Abstract available
    
    

    
    J Clin Invest

44. BORCSOK J, Gopaul D, Devesa-Serrano D, Mooser C, et al
    Quantitative functional profiling of ERCC2 mutations deciphers cisplatin sensitivity in bladder cancer.
    J Clin Invest. 2025;135:e186688.
    PubMed         Abstract available
    
    

    
    J Histotechnol

45. PATEL AU, Atiya S, Song Y, Chu W, et al
    Novel liquid immunocytochemistry with machine learning analysis for bladder cancer detection.
    J Histotechnol. 2025 Aug 15:1-9. doi: 10.1080/01478885.2025.2546655.
    PubMed         Abstract available
    
    

    
    J Magn Reson Imaging

46. KONG L, Qin Y, Li H, Cai Q, et al
    Development and Validation of a Preoperative MRI Habitat Radiomics Model to Predict Variant Histology in Bladder Cancer.
    J Magn Reson Imaging. 2025 Aug 20. doi: 10.1002/jmri.70069.
    PubMed         Abstract available
    
    

    
    J Robot Surg

47. FAN G, Zhu X, Chen Y, Cai S, et al
    Comparative outcomes of intracorporeal and extracorporeal urinary diversion in robotic cystectomy: a systematic review and meta-analysis.
    J Robot Surg. 2025;19:512.
    PubMed         Abstract available
    
    

    
    J Transl Med

48. WANG Y, Song W, Feng C, Wu S, et al
    Correction: Multi-omics analysis unveils the predictive value of IGF2BP3/SPHK1 signaling in cancer stem cells for prognosis and immunotherapeutic response in muscle-invasive bladder cancer.
    J Transl Med. 2025;23:909.
    PubMed        
    
    

    
    Lancet Infect Dis

49. MEDINA C, Garcia V, Gutierrez A, Caicedo JI, et al
    Urachal actinomycosis mimicking a urachal adenocarcinoma: case report and systematic review.
    Lancet Infect Dis. 2025;25:e533-e539.
    PubMed         Abstract available
    
    

    
    Mikrochim Acta

50. SUN J, Yang H, Zhuang J, Chen R, et al
    Copper single-atom-based flexible aptamer biochip for simultaneous monitoring of bladder cancer-related bacteria.
    Mikrochim Acta. 2025;192:602.
    PubMed         Abstract available
    
    

    
    Mol Carcinog

51. 
    RETRACTION: SENP2 Suppresses Epithelial-Mesenchymal Transition of Bladder Cancer Cells Through deSUMOylation of TGF-betaRI.
    Mol Carcinog. 2025 Aug 25. doi: 10.1002/mc.70038.
    PubMed         Abstract available
    
    

    
    Mol Med Rep

52. YAN L, Su P, Sun X
    Role of the tumor microenvironment in promoting treatment resistance in urothelial carcinoma (Review).
    Mol Med Rep. 2025;32:293.
    PubMed         Abstract available
    
    

    
    Nat Rev Urol

53. ECKE TH, Collen S, Filicevas A, Yfantis T, et al
    Urinary bladder cancer needs more attention - recommendations for health care professionals and politicians in the European Union.
    Nat Rev Urol. 2025 Aug 19. doi: 10.1038/s41585-025-01077.
    PubMed         Abstract available
    
    

    
    NPJ Precis Oncol

54. ZHANG M, Zhao Y, Hao D, Song Y, et al
    An interpretable CT-based deep learning model for predicting overall survival in patients with bladder cancer: a multicenter study.
    NPJ Precis Oncol. 2025;9:288.
    PubMed         Abstract available
    
    

    
    PLoS One

55. HU C, Wang F, Xu H, Dong X, et al
    Deep learning-based spatial analysis on tumor and immune cells of pathology images predicts MIBC prognosis.
    PLoS One. 2025;20:e0328816.
    PubMed         Abstract available
    
    

    
    Proteomes

56. ALANAZI F, Sharif A, Kidd M, Keevill EJ, et al
    Cell Surface Proteomics Reveals Hypoxia-Regulated Pathways in Cervical and Bladder Cancer.
    Proteomes. 2025;13:36.
    PubMed         Abstract available
    
    

    
    Radiat Oncol

57. FISCHER J, Fischer LA, Bensberg J, Bojko N, et al
    CBCT-based online adaptive radiotherapy of the bladder - geometrical and dosimetrical considerations compared to conventional IGRT.
    Radiat Oncol. 2025;20:128.
    PubMed         Abstract available
    
    

    
    Sci Rep

58. SANO K, Shiga M, Ferdousi F, Sakurai H, et al
    A novel, synthesized, amphiphilic ethylene glycol squalene derivative suppresses BBN-induced bladder carcinogenesis.
    Sci Rep. 2025;15:30751.
    PubMed         Abstract available
    
    
59. SUN FZ, Liu YX, Xu QL, Guo LX, et al
    Oncological outcome and survival predictors of widowed patients with bladder cancer in special populations.
    Sci Rep. 2025;15:30638.
    PubMed         Abstract available
    
    
60. VELISKOVA M, Masarovicova D, Waczulikova I, Kollarik B, et al
    The role of spectral characteristics of urine in bladder cancer diagnostics.
    Sci Rep. 2025;15:29979.
    PubMed         Abstract available
    
    

    
    Toxicol Res (Camb)

61. YANG B, Pan M, Tao T, Chen K, et al
    Tanshinone IIA promotes METTL3/METTL14-mediated FDX1 m6A modification to induce cuproptosis in bladder cancer.
    Toxicol Res (Camb). 2025;14:tfaf123.
    PubMed         Abstract available
    
    

    
    Urol Oncol

62. HIGGINS MI, Gabrielson AT, Su ZT, Feng M, et al
    Molecular classification of nonurothelial histologic subtypes of bladder cancer.
    Urol Oncol. 2025 Aug 20:S1078-1439(25)00277.
    PubMed         Abstract available
    
    
63. GARJE R, Ravindra A, Rahim B, Kroll M, et al
    Avelumab and taxol chemotherapy in platinum-refractory or ineligible metastatic urothelial carcinoma (AVETAX trial).
    Urol Oncol. 2025;43:520.
    PubMed         Abstract available
    
    
64. TEPLITSKY SL, Cranford W, Kim JK, Bell S, et al
    Prognostic significance of pathologic response to neoadjuvant chemotherapy in muscle-invasive urothelial carcinoma of the bladder with histologic subtype.
    Urol Oncol. 2025;43:521.
    PubMed         Abstract available
    
    
65. TASAKA R, Kobatake K, Kohada Y, Takemoto K, et al
    KDM6A deficiency promotes 5-aminolevulinic acid-mediated photodynamic therapy resistance in bladder cancer by suppressing ROS accumulation.
    Urol Oncol. 2025 Aug 21:S1078-1439(25)00280.
    PubMed         Abstract available
    
    
66. GOTO K, Kohada Y, Kobatake K, Tasaka R, et al
    Impact of the preoperative modified 5-item frailty index on the efficacy of neoadjuvant chemotherapy in patients with muscle invasive bladder cancer.
    Urol Oncol. 2025 Aug 21:S1078-1439(25)00283.
    PubMed         Abstract available
    
    
67. STERNBERG CN, Squifflet P, Saad ED, Burdett S, et al
    Evaluating surrogates for overall survival in the adjuvant treatment of bladder cancer with chemotherapy.
    Urol Oncol. 2025 Aug 21:S1078-1439(25)00269.
    PubMed         Abstract available
    
    
68. RIZZO A, Valenti A
    Advancing age- and gender-sensitive supportive care and follow-up strategies in bladder cancer.
    Urol Oncol. 2025 Aug 23:S1078-1439(25)00276.
    PubMed        
    
    

    
    Urol Pract

69. FADEL A, Findlay BL, Pinkhasov AM, Sharma V, et al
    Variability in Health Care Utilization and Perioperative Outcomes Among Urinary Diversion Patients: Analysis of the National Surgical Quality Improvement Program Database.
    Urol Pract. 2025;12:548-556.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Bladder Cancer is free of charge.